Gilead Sciences (NASDAQ: GILD) insider details RSU vesting, share sale

Rhea-AI Filing Summary

Gilead Sciences Chief Commercial Officer Johanna Mercier reported routine equity award activity involving restricted stock units and company shares. On 12/10/2025, 3,842 restricted stock units converted into an equal number of Gilead common shares. On the same date, 1,814 shares of common stock were disposed of in a transaction coded "F," indicating shares were withheld or used to cover tax obligations at a price of $121.34 per share.

After these transactions, Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units. Each restricted stock unit represents the contingent right to receive one share, and the units follow a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining units vesting 6.25% quarterly until fully vested.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		M		3,842	A	(1)	111,035	D
Common Stock	12/10/2025		F		1,814	D	$121.34	109,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	12/10/2025		M			3,842	(2)	(2)	Common Stock	3,842	(1)	27,674	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Johanna Mercier	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Gilead Sciences (GILD) report for Johanna Mercier?

Gilead Sciences reported that Johanna Mercier, its Chief Commercial Officer, had 3,842 restricted stock units convert into common stock on 12/10/2025, and she disposed of 1,814 shares in a transaction coded "F," reflecting shares used or withheld to satisfy tax obligations at $121.34 per share.

How many Gilead Sciences (GILD) shares does Johanna Mercier own after the reported transactions?

Following the reported activity, Johanna Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units, each of which represents the right to receive one share of common stock.

What was the price for the Gilead (GILD) shares disposed of by Johanna Mercier?

The 1,814 Gilead common shares disposed of in the transaction coded "F" were valued at $121.34 per share, consistent with shares withheld or delivered to satisfy tax obligations associated with equity vesting.

How do Johanna Mercier's restricted stock units in Gilead Sciences (GILD) vest?

The restricted stock units follow a four-year vesting schedule. 25% vest on the first anniversary of the grant date, and the remaining balance vests at 6.25% quarterly thereafter until fully vested.

What is Johanna Mercier’s role and relationship to Gilead Sciences (GILD)?

Johanna Mercier is reported as an officer of Gilead Sciences with the title Chief Commercial Officer. She is not listed as a director or a 10% owner, and the Form 4 is filed for a single reporting person.

What type of securities were involved in Johanna Mercier’s Gilead (GILD) transactions?

The transactions involved Gilead common stock and restricted stock units. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock upon vesting.